FIELD: chemistry.
SUBSTANCE: invention relates to biotechnology, specifically to fibroblast growth factor receptor (FGFR) hybrid proteins and can be used in medicine to treat diseases associated with excessive FGF expression. A soluble FGFR fused protein is constructed, which consists of a fragment derived from an intermediate functional sequence (IFS) of a FGFR Ig-like domain, a second FGFR Ig-like domain (D2), a third FGFR Ig-like domain (D3) and an immunoglobulin Fc region. The obtained fused protein is used to inhibit angiogenesis in mammals.
EFFECT: invention increases affinity of binding with FGF.
11 cl, 6 dwg, 3 tbl, 7 ex
| Title |
Year |
Author |
Number |
| ANTIANGIOGENIC INDUCER FUSION PROTEIN AND USING IT |
2012 |
|
RU2560589C2 |
| BIFUNCTIONAL ANGIOGENESIS INHIBITOR AND ITS APPLICATION |
2019 |
- Jiang, Jing
- Fang, Jianmin
- Luan, Xuejing
- Yao, Xuejing
- Wang, Ling
|
RU2760738C1 |
| HOMODIMERIC FUSED PROTEIN WITH ACTIVITY OF ANGIOGENESIS INHIBITOR (VARIANTS), DNA MOLECULE ENCODING HOMODIMERIC FUSED PROTEIN, VECTOR FOR EXPRESSION OF HOMODIMERIC FUSED PROTEIN, METHOD FOR TRANSFECTION OF MAMMALIAN CELL AND METHOD FOR PREPARING HOMODIMERIC FUSED PROTEIN |
1999 |
- Lo Kin-Ming
- Li Jue
- Dzhilliz Stefen D.
|
RU2240328C2 |
| CHIMERIC PROTEINS, INHIBITING ANGIOGENESIS, AND THEIR APPLICATION |
2005 |
|
RU2355414C2 |
| ANTIBODIES SPECIFICALLY BINDING TYPE 1 RECEPTOR OF FIBROBLAST GROWTH FACTOR, ANTIBODIES APPLICATION FOR ONCOLOGICAL DISEASE TREATMENT, METHOD FOR ANTIBODIES PRODUCTION |
2015 |
|
RU2638457C2 |
| ALK1 ANTAGONISTS AND THEIR APPLICATION IN THE TREATMENT OF KIDNEY-CELLULAR CARCINOMA |
2013 |
- Bkhatt Rupal S.
- Kumar Ravindra
- Majer Dzhejms V.
- Pirsoll Robert
- Sherman Mettyu
- Solban Nikolas
|
RU2633638C2 |
| EXTRACELLULAR DOMAIN OF TYROSINE KINASE RECEPTOR, ALLOSTERIC BINDING INHIBITOR |
2010 |
- Karmele Peter
- De Smet Frederik
- Skhimkovitz Jost
- Russo Frederik
- Erber Koranten
|
RU2604805C2 |
| ENHANCEMENT OF IMMUNE RESPONSES MEDIATED BY PROTEINS FUSED FROM ANTIBODY AND CYTOKINE BY METHOD OF COMBINED ADMINISTRATION OF ANGIOGENESIS INHIBITOR |
1999 |
|
RU2229305C2 |
| FUSED PROTEIN ELICITING BIOLOGICAL ACTIVITY OF INTERFERON-ALPHA, DIMERIC FUSED PROTEIN, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF, DNA MOLECULE (VARIANTS) AND METHOD FOR TARGETING INTERFERON-ALPHA INTO LIVER TISSUE |
2000 |
- Sun Japing
- Dzhilliz Stefen D.
- Lo Kin-Ming
|
RU2262510C9 |
| ANTAGONISTS OF ALK1 RECEPTOR AND LIGANDS AND THEIR APPLICATION |
2007 |
- Grinberg, Asja
- Nopf, Dzhon
- Kumar, Ravindra
- Pirsall, Robert, Skott
- Sikhra, Dzhasbir
|
RU2559532C2 |
